Risk of breast cancer among women diagnosed with Hodgkin Lymphoma (HL) at age 30 years or younger according to radiotherapy and family history of breast/ovarian cancer in first- or second-degree relatives
. | Data from all women: patients, n = 105 and matched control subjects, n = 266‡ . | . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic . | Exposure . | Cases, no (%) . | Controls, no. (%) . | Adjusted OR (95% CI) . | Effect ≥ 5 Gy, OR (95% CI) . | . | |||||
| FH* | RT > 5 Gy | No FH* | Positive FH* | ||||||||
| No | No | 8 (7.6) | 53 (19.9) | 1.0 (reference) | 1.0 (reference) | — | |||||
| No | Yes | 38 (36.2) | 76 (28.6) | 5.8 (2.1-16.3) | 5.8 (2.1-16.3) | — | |||||
| Yes | No | 8 (7.6) | 7 (2.6) | 11.5 (2.5-52.6) | — | 1.0 (reference) | |||||
| Yes | Yes | 20 (19.0) | 21 (7.9) | 9.5 (3.0-30.1)§ | — | 0.8 (0.2-3.4) | |||||
| Unknown | — | 31 (29.5) | 109 (41.0) | — | — | — | |||||
. | Data from all women: patients, n = 105 and matched control subjects, n = 266‡ . | . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic . | Exposure . | Cases, no (%) . | Controls, no. (%) . | Adjusted OR (95% CI) . | Effect ≥ 5 Gy, OR (95% CI) . | . | |||||
| FH* | RT > 5 Gy | No FH* | Positive FH* | ||||||||
| No | No | 8 (7.6) | 53 (19.9) | 1.0 (reference) | 1.0 (reference) | — | |||||
| No | Yes | 38 (36.2) | 76 (28.6) | 5.8 (2.1-16.3) | 5.8 (2.1-16.3) | — | |||||
| Yes | No | 8 (7.6) | 7 (2.6) | 11.5 (2.5-52.6) | — | 1.0 (reference) | |||||
| Yes | Yes | 20 (19.0) | 21 (7.9) | 9.5 (3.0-30.1)§ | — | 0.8 (0.2-3.4) | |||||
| Unknown | — | 31 (29.5) | 109 (41.0) | — | — | — | |||||
—indicates not calculated; reference, the reference group for the odds ratio comparison.
†Analyses were adjusted for ovarian radiation dose, and number of cycles of AA chemotherapy.
History of breast and/or ovarian cancer in a first or second degree relative.
Women who had an unknown breast radiation dose (n = 1 patient; 7 control subjects) or an unknown ovarian dose (n = 4 control subjects) were assigned the median dose in controls (2300 cGy and 44.5 cGy, respectively) in these analyses.
Interaction OR (multiplicative scale): breast dose of 5 Gy or more and 1st or 2nd degree family history, 0.14 (95% CI, 0.03-0.81); breast dose on a continuous scale and 1st or 2nd degree family history, 0.93 (95% CI, 0.89-0.99); breast dose on a continuous scale and 1st degree family history (14 patients, 15 control subjects), 0.91 (95% CI, 0.85-0.98). Interaction contrast ratio (ICR; additive RR scale): breast dose of 5 Gy or more and 1st or 2nd degree family history, -6.8 (95% CI, -52.4-+7.8); modified breast dose on a continuous scale and 1st or 2nd degree family history, -0.22 (95% CI, -1.1-+0.27); modified breast dose on a continuous scale and 1st degree family history, -0.33 (95% CI, not estimated to +.03).